Paradigm Spine, LLC has a new leader to guide U.S. sales of the company’s lead product—coflex Interlaminar Stabilization.
Tim Hein: New VP of Sales at Paradigm Spine

Tim Hein, a 20-year veteran of the medical device industry, has prior leadership experience at Zimmer Biomet Spine, LDR Spine, Medtronic, DePuy Spine, and Ethicon Endo-Surgery. Hein earned his B.S. in Engineering from the United States Military Academy at West Point and his MBA from Pacific Lutheran University.
“With published datasets of long-term Level 1 evidence from two prospective, randomized, controlled clinical studies, comparing coflex versus decompression plus fusion and more recently coflex versus decompression alone, we have entered a major inflection point for the company where we can conclusively show that coflex demonstrates composite clinical success for patients with spinal stenosis,” said Marc Viscogliosi, chairman and CEO of Paradigm Spine, in the March 26, 2018 news release.
“Based on this, and the recent NASS [North American Spine Society] Coverage Recommendation for coflex for interlaminar stabilization, it becomes of paramount importance to strengthen both our technology development and sales and marketing teams to help educate surgeons, practices, patients, their families and the broader spine community on coflex as the motion-preserving lumbar option.”
Tim Hein told OTW, “The combination of innovative technology, market creation sales leadership experiences developed throughout my medical device career at Ethicon Endo-Surgery, Kyphon and LDR Spine. In terms of pure leadership, my experience as an Army officer was invaluable.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.